Archives
MLN8237 (Alisertib): Selective Aurora A Kinase Inhibitor ...
MLN8237 (Alisertib): Selective Aurora A Kinase Inhibitor for Cancer Research
Executive Summary: MLN8237 (Alisertib) is a potent, ATP-competitive inhibitor of Aurora A kinase (AAK), with a Ki of 0.43 nM and over 200-fold selectivity versus Aurora B kinase (APExBIO). In cancer cell lines, MLN8237 induces apoptosis at concentrations as low as 50 nM, confirmed by cleaved PARP accumulation. In animal models, oral dosing at 20–30 mg/kg achieves tumor growth inhibition rates of 49–51%. The compound is soluble at ≥25.95 mg/mL in DMSO but insoluble in water and ethanol, requiring careful preparation. MLN8237 is intended exclusively for research use and is not approved for diagnostic or clinical applications (Bernacki et al., 2019).
Biological Rationale
Aurora A kinase (AAK) is a serine/threonine kinase essential for mitotic entry, spindle assembly, and chromosome alignment. AAK is overexpressed in a range of tumor types, including hematologic malignancies and solid tumors (Bernacki et al., 2019). Dysregulation of Aurora kinases, particularly AAK, disrupts normal mitosis, leading to aneuploidy, which is a hallmark of cancer cells (Bernacki et al., 2019). Selective Aurora A kinase inhibition therefore represents a rational anti-cancer strategy, targeting a validated oncogenic pathway (MolecularBeacon—this article provides protocol details, which are extended here by mechanistic precision and benchmarked data).
Mechanism of Action of MLN8237 (Alisertib)
MLN8237 is an ATP-competitive, reversible inhibitor of Aurora A kinase. It binds to the ATP-binding pocket of AAK with a Ki of 0.43 nM and inhibits kinase activity with an IC50 of 1.2 nM (APExBIO). Selectivity profiling demonstrates more than 200-fold preference for Aurora A over Aurora B kinase, minimizing off-target effects. Inhibition of AAK by MLN8237 disrupts centrosome maturation and spindle assembly, leading to mitotic arrest, polyploidy, and apoptosis. Induction of cell death is confirmed by increased cleaved PARP in treated cancer lines, including TIB-48 and CRL-2396, at concentrations starting from 50 nM (Bernacki et al., 2019).
Evidence & Benchmarks
- MLN8237 (Alisertib) inhibits Aurora A kinase with a Ki of 0.43 nM and an IC50 of 1.2 nM in biochemical assays (APExBIO).
- Demonstrates >200-fold selectivity for Aurora A versus Aurora B kinase, reducing off-target kinase inhibition (APExBIO).
- Induces apoptosis in TIB-48 and CRL-2396 cancer cell lines in a dose-dependent manner, with effective concentrations starting at 50 nM; confirmed by cleaved PARP levels (Bernacki et al., 2019).
- Oral administration of 20–30 mg/kg in animal models yields tumor growth inhibition rates of 49–51% (APExBIO).
- In the Aneugen Molecular Mechanism Assay, Aurora kinase inhibitors like MLN8237 reduce the p-H3:Ki-67-positive nuclei ratio, confirming specific mitotic kinase inhibition (Bernacki et al., 2019).
- MLN8237 exhibits high solubility in DMSO (≥25.95 mg/mL) but is insoluble in water and ethanol; solutions should be freshly prepared and stored at -20°C (APExBIO).
This article updates and extends the detailed scenario-based integration strategies described in Survivin.net by providing additional quantitative benchmarks and mechanistic clarity for MLN8237.
Applications, Limits & Misconceptions
MLN8237 is widely used for dissecting the Aurora kinase signaling pathway in cancer biology, studying oncogenesis, apoptosis induction, and mechanisms of tumor progression. Its high specificity makes it valuable for validating Aurora A-dependent phenotypes in cell viability and proliferation assays. However, it is not a pan-Aurora inhibitor and has limited activity against Aurora B and C kinases. MLN8237 is not suitable for clinical or diagnostic use, and all experiments must be performed within the boundaries of research-only applications (Prostigmin.com—that article emphasizes general workflows; here, we focus on evidence-based selectivity and pitfalls).
Common Pitfalls or Misconceptions
- MLN8237 does not inhibit tubulin polymerization directly; its primary target is Aurora A kinase (Bernacki et al., 2019).
- It is not effective as a pan-Aurora inhibitor; selectivity is >200-fold for Aurora A versus Aurora B.
- MLN8237 is not water or ethanol soluble; improper solvent use leads to precipitation and assay failure.
- Intended for in vitro and in vivo research; not validated or approved for use in humans or diagnostics.
- Stock solutions should not be stored long-term at room temperature; they require -20°C storage and are best used fresh.
Workflow Integration & Parameters
MLN8237 (Alisertib, SKU A4110 from APExBIO) is formulated as a solid (molecular weight 518.92, formula C27H20ClFN4O4). For cell-based assays, dissolve at ≥25.95 mg/mL in DMSO with brief warming or ultrasonic treatment. Prepare working concentrations (e.g., 50–500 nM) by dilution into culture media; avoid water or ethanol as solvents. Store powder and stock at -20°C. For in vivo animal studies, oral administration at 20–30 mg/kg has been validated for tumor regression endpoints. Monitor vehicle controls for DMSO-related effects. For apoptosis induction, monitor cleaved PARP and cell viability markers 24–48 hours post-treatment (Pentynoic-acid-stp-ester.com—while that review highlights aneugenicity, this article delivers practical integration steps and physicochemical details).
Conclusion & Outlook
MLN8237 (Alisertib) is a potent, selective Aurora A kinase inhibitor that enables high-precision studies of mitotic regulation and tumor biology. Its robust selectivity and validated anti-tumor efficacy support its use as a gold-standard research tool. Future research may extend to combinatorial regimens and mechanistic dissection of resistance pathways. Researchers should adhere to recommended storage, solubility, and application parameters for reproducible results. For further details on selective Aurora A kinase inhibition, see the official product page.